Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
Andreas Wollenberg, Maria Kinberger, B.W.M. Arents, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 9, pp. 1409-1431
Open Access | Times Cited: 244

Showing 1-25 of 244 citing articles:

Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
Pavel Kolkhir, Cezmi A. Akdiş, Mübeccel Akdiş, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 9, pp. 743-767
Closed Access | Times Cited: 64
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Svenja Müller, Laura Maintz, Thomas Bieber
Allergy (2024) Vol. 79, Iss. 6, pp. 1501-1515
Open Access | Times Cited: 45
OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target
Michael Croft, Ehsanollah Esfandiari, Camilla Chong, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 3, pp. 447-461
Open Access | Times Cited: 29
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 919-932
Open Access | Times Cited: 17
Overview of Atopic Dermatitis in Different Ethnic Groups
Andrea Chiricozzi, Martina Maurelli, Laura Calabrese, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 7, pp. 2701-2701
Open Access | Times Cited: 36
Atopic dermatitis in children and adults
Andreas Wollenberg, Thomas Werfel, Johannes Ring, et al.
Deutsches Ärzteblatt international (2023)
Open Access | Times Cited: 30
Is Atopic Dermatitis Only a Skin Disease?
Alicja Mesjasz, Marta Zawadzka, Maciej Chałubiński, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 1, pp. 837-837
Open Access | Times Cited: 26
Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results
J Rodríguez, Pedro Herranz, Ricardo Ruíz‐Villaverde, et al.
Clinical and Experimental Dermatology (2023) Vol. 48, Iss. 9, pp. 991-997
Closed Access | Times Cited: 22
Treatable Traits in Asthma: The Importance of Extrapulmonary Traits—GERD, CRSwNP, Atopic Dermatitis, and Depression/Anxiety
Vanessa M. McDonald, Yuto Hamada, Álvar Agustí, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024) Vol. 12, Iss. 4, pp. 824-837
Closed Access | Times Cited: 13
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry
Junfen Zhang, Celeste M. Boesjes, Laura Loman, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 2, pp. 300-311
Open Access | Times Cited: 11
Combining treat‐to‐target principles and shared decision‐making: International expert consensus‐based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis
Jonathan I. Silverberg, Melinda Gooderham, Norito Katoh, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 11, pp. 2139-2148
Open Access | Times Cited: 9
Biologics and small molecules: the re-evolution in the treatment of atopic dermatitis in children and adolescents. Current state of the art and future perspectives
Enza D’Auria, Cristiana Indolfi, Miriam Acunzo, et al.
Expert Review of Clinical Immunology (2025)
Closed Access | Times Cited: 1
Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study
Luigi Gargiulo, Luciano Ibba, Andrea Cortese, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 2, pp. 651-660
Open Access | Times Cited: 20
Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis
Raquel Leão Orfali, Valéria Aoki
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 577-577
Open Access | Times Cited: 20
First update of the living European guideline (EuroGuiDerm) on atopic eczema
Andreas Wollenberg, Maria Kinberger, B.W.M. Arents, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 11
Open Access | Times Cited: 19
Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis
C. Ertus, Lucie‐Marie Scailteux, Alain Lescoat, et al.
British Journal of Dermatology (2023) Vol. 189, Iss. 4, pp. 368-380
Closed Access | Times Cited: 18
Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience
Luigi Gargiulo, Luciano Ibba, Carlo Alberto Vignoli, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 16
Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review
Luciano Ibba, Luigi Gargiulo, Carlo Alberto Vignoli, et al.
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 593-604
Open Access | Times Cited: 7
Lebrikizumab: First Approval
Susan J. Keam
Drugs (2024) Vol. 84, Iss. 3, pp. 347-353
Closed Access | Times Cited: 7
Dupilumab Treatment in Pediatric Patients Aged 6–11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review
Michael J. Cork, Simon G. Danby, Ana B. Rossi, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 277-289
Open Access | Times Cited: 6
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series
Niccolò Gori, Elena Ippoliti, Silvia Ferrucci, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 10
Closed Access | Times Cited: 6
Effectiveness and safety of upadacitinib for moderate‐to‐severe atopic dermatitis in a real‐world setting: A 52‐week retrospective study
Luigi Gargiulo, Luciano Ibba, Francesco Piscazzi, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 2
Open Access | Times Cited: 15
Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis
Mário Pedro Marques, Carla Varela, Laura Mendonça, et al.
Pharmaceutics (2023) Vol. 15, Iss. 6, pp. 1724-1724
Open Access | Times Cited: 14
Anti-inflammatory and biologic drugs for atopic dermatitis: a therapeutic approach in children and adolescents
Carlo Caffarelli, Arianna Giannetti, Giuliana Giannì, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 13
Upadacitinib improves symptoms of concomitant allergic rhinitis or allergic asthma in patients with severe atopic dermatitis: A 16‐week multicentre retrospective study
Luigi Gargiulo, Luciano Ibba, Francesco Piscazzi, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 9
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top